Literature DB >> 2990103

Varicella-zoster virus envelope glycoproteins: biochemical characterization and identification in clinical material.

C M Edson, B A Hosler, C A Poodry, R T Schooley, D J Waters, D A Thorley-Lawson.   

Abstract

Varicella-zoster virus (VZV)-infected human foreskin fibroblasts synthesize viral glycoproteins of 125,000 (gp125), 118,000 (gp118), 92,000 (gp92), 63,000 (gp63), 59,000 (gp59), and 47,000 (gp47) Da. In biochemical studies, all of these VZV glycoproteins were shown to contain asparagine-linked (N-linked) oligosaccharide chains and, except for gp125 and gp47, to be sialoglycoproteins. Experiments with endo-beta-N-acetylglucosaminidase H (endo H) demonstrated that gp92 contained only complex type (endo H-resistant) N-linked glycosyl chains, while the other mature glycoproteins contained both high-mannose (endo H-sensitive) and complex-type oligosaccharides. Monoclonal antibodies recognizing multiple glycoproteins, gp63/gp125 or gp92/gp59/gp47, neutralized virus infection, suggesting the glycoproteins were important components of the virus envelope. This was confirmed for gp92/gp59/gp47 by immunoelectron microscopy, which revealed dense staining localized exclusively to the virion envelope and to the plasma membrane of virus-producer cells. The mature forms of all of these glycoproteins were also present in viral material isolated from vesicles of varicella and zoster patients, indicating that in infected individuals the viral glycoproteins are synthesized and processed in a manner similar to that in tissue culture cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2990103     DOI: 10.1016/0042-6822(85)90201-6

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  17 in total

1.  Differentiated neuroblastoma cells provide a highly efficient model for studies of productive varicella-zoster virus infection of neuronal cells.

Authors:  Jenna Christensen; Megan Steain; Barry Slobedman; Allison Abendroth
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Infection and Functional Modulation of Human Monocytes and Macrophages by Varicella-Zoster Virus.

Authors:  Megan Steain; Barry Slobedman; Allison Abendroth; Jarrod J Kennedy
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

3.  Cross-reactivity between herpes simplex virus glycoprotein B and a 63,000-dalton varicella-zoster virus envelope glycoprotein.

Authors:  C M Edson; B A Hosler; R A Respess; D J Waters; D A Thorley-Lawson
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

4.  Easy and reliable double-immunogold labelling of herpes simplex virus type-1 infected cells using primary monoclonal antibodies and studied by cryosection electron microscopy.

Authors:  H L Jensen; B Norrild
Journal:  Histochem J       Date:  1999-08

5.  Varicella-Zoster Virus Glycoproteins: Entry, Replication, and Pathogenesis.

Authors:  Stefan L Oliver; Edward Yang; Ann M Arvin
Journal:  Curr Clin Microbiol Rep       Date:  2016-09-09

6.  Assembly and processing of the disulfide-linked varicella-zoster virus glycoprotein gpII(140).

Authors:  E A Montalvo; C Grose
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

7.  New common nomenclature for glycoprotein genes of varicella-zoster virus and their glycosylated products.

Authors:  A J Davison; C M Edson; R W Ellis; B Forghani; D Gilden; C Grose; P M Keller; A Vafai; Z Wroblewska; K Yamanishi
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

8.  An 88,000-Mr Giardia lamblia surface protein which is immunogenic in humans.

Authors:  C M Edson; M J Farthing; D A Thorley-Lawson; G T Keusch
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

9.  Identification of the phosphorylation sequence in the cytoplasmic tail of the varicella-zoster virus Fc receptor glycoprotein gpI.

Authors:  Z Yao; W Jackson; C Grose
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

10.  Characterization and immunogenicity of a candidate subunit vaccine against varicella-zoster virus.

Authors:  J Davies; J A Hallworth; P McLeish; S Randall; B A Martin; A Buchan; G R Skinner
Journal:  Med Microbiol Immunol       Date:  1994-05       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.